Inflammatory and immune-mediated diseases

A cross-sectional and multidisciplinary group focused on clinical and translational research of inflammatory and immune-mediated diseases, including autoinflammatory and autoimmune diseases. It promotes its own studies and participates in both national and international multicentre projects, with an observational and interventional design. It has been a promoter of both funded and independent clinical trials. 

Lines of research:

• Characterisation of patients with systemic or autoinflammatory autoimmune diseases as well as those induced by Covid 19 treated at the Systemic Autoimmune Diseases Unit of the HUN (UEAS-HUN).
• Efficacy studies with corticosteroids and IL-1 inhibitors in Covid 19 pneumonia.
• Promotion and collaboration with clinical trials related to systemic or autoinflammatory autoimmune diseases as well as those induced by Covid 19.
• Clinical and prognostic characterisation of autoimmune diseases in pregnancy and puerperium.
• Characterisation of patients with uveitis, scleritis, episcleritis and ocular inflammatory pathology treated at (UEAS-HUN).
• Identification of risk markers of immune-mediated toxicity in cancer patients treated with immune checkpoint inhibitors.
  COVID-19-induced autoimmune disorders
• Characterisation of patients with long COVID and systemic autoimmune disorders induced by COVID-19 and research on autoinflammatory therapies.
• Long COVID